Gandotinib
Clinical data | |
---|---|
Routes of administration | PO |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H25ClFN7O |
Molar mass | 469.95 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Gandotinib (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 (Janus kinase) inhibitor, with additional minor inhibition of STAT3.
In a phase I trial, 16% of patients receiving the drug developed tumor lysis syndrome.[1] A phase II trial is underway for patients with myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, or myelofibrosis, who had failed ruxolitinib.[2][3]
References
- ↑ "Gandotinib - Eli Lilly". AdisInsight. Springer Nature Switzerland AG.
- ↑ Clinical trial number NCT01594723 for "A Study of LY2784544 in Participants With Myeloproliferative Neoplasms" at ClinicalTrials.gov
- ↑ Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, Verma A, Hamid O, Walgren R, Pitou C, Li PL, Gerds AT (August 2018). "Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms". Leukemia Research. 71: 82–88. doi:10.1016/j.leukres.2018.06.014. PMID 30025280.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.